PDUFA VIII: A Blueprint For A More Predictable FDA

The Prescription Drug User Fee Act, or PDUFA, allows the U.S. Food and Drug Administration (FDA) to collect fees from pharmaceutical and biotechnology companies to help fund its review of new drugs and biologics. First enacted in 1992 and renewed every five years, the program pairs those resources with performance goals intended to make FDA reviews timely and predictable. 

A proposed PDUFA VIII commitment letter was released by the FDA recently and outlines how the agency intends to review innovative medicines from fiscal years 2028-2032. 

These timelines do not guarantee approval, but they give companies a more dependable framework for clinical planning, capital requirements, partnerships and commercialization. 

Earlier communication could reduce delays 

The proposal seeks to improve interactions between FDA and sponsors throughout development and application review. It directs FDA to prioritize questions involving pivotal protocols, potentially helping companies address concerns about trial design, endpoints or analysis before beginning registrational studies. 

PDUFA VIII would also commission an independent assessment of first-cycle reviews. The study would examine approvals, complete response letters, review extensions and FDA-sponsor communications to identify why some medicines are not approved during their initial review cycle. 

Greater visibility into recurring problems could help sponsors prepare stronger submissions while increasing accountability for FDA’s review practices. 

Manufacturing takes center stage 

Chemistry, Manufacturing and Controls deficiencies can delay an otherwise approvable product. The proposal would create CMC facility pre-submission meetings, generally three to six months before an NDA or BLA filing. Topics could include supply-chain risks, facility dependencies and inspection history. 

Sponsors could also request meetings after certain facility inspections to discuss findings that might lead to a complete response action and determine whether corrective measures are possible within the current review cycle. 

For biotech companies relying on contract manufacturers, the message is particularly important: facility readiness must be addressed early and treated as part of the regulatory strategy. 

Support for emerging regulatory science 

The letter continues initiatives involving model-informed drug development, innovative trial designs, biomarkers, patient-focused development and real-world evidence. 

Rare-disease developers may benefit from continued FDA engagement on novel endpoints, adaptive designs and natural-history data. The Rare Disease Endpoint Advancement program would continue, complemented by up to 10 Rare Disease Innovation, Science and Exploration workshops. 

The proposal also reinforces FDA’s cell and gene therapy capabilities, including expertise in advanced manufacturing, artificial intelligence and evidence generation for small patient populations.